37
Participants
Start Date
January 29, 2019
Primary Completion Date
June 29, 2021
Study Completion Date
June 29, 2021
Efzofitimod 1.0 mg/kg or Placebo
Participants to receive efzofitimod 1.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 3.0 mg/kg or Placebo
Participants to receive efzofitimod 3.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Efzofitimod 5.0 mg/kg or Placebo
Participants to receive efzofitimod 5.0 mg/kg IV every 4 weeks or placebo matched to efzofitimod every 4 weeks
Inova Fairfax Medical Center, Falls Church
East Carolina University, Greenville
Emory University, Atlanta
aTyr Investigative Site, Miami
University of Louisville, Louisville
Cleveland Clinic, Cleveland
University of Cincinnati, Cincinnati
University of Iowa, Iowa City
Northwestern University, Chicago
aTyr Investigative Site, Chicago
UT Southwestern Medical Center, Dallas
National Jewish Health, Denver
aTyr Investigative Site, Northridge
Medical University of South Carolina, Charleston
University of Alabama, Birmingham
Foundation for Sarcoidosis Research
OTHER
aTyr Pharma, Inc.
INDUSTRY